<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066637</url>
  </required_header>
  <id_info>
    <org_study_id>09-0986</org_study_id>
    <secondary_id>201106273</secondary_id>
    <nct_id>NCT01066637</nct_id>
  </id_info>
  <brief_title>iNOS With Positron Emission Tomography (PET) in Cellular Inflammation.</brief_title>
  <acronym>F-NOS</acronym>
  <official_title>Imaging iNOS Activity Using [18F] (+/-) NOS With Positron Emission Tomography (PET) in Cellular Inflammation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to measure the level of an enzyme in a patient's heart&#xD;
      called inducible nitric oxide synthase(iNOS) using Positron Emission Tomography (PET) imaging&#xD;
      with a radioactive tracer called 18F-NOS. These PET results will be compared to tissue&#xD;
      results obtained during routine endomyocardial heart biopsy. The enzyme iNOS produces nitric&#xD;
      oxide in inflammatory diseases such as acute heart transplant rejection, diabetes,&#xD;
      Alzheimer's and cancer. Thus, PET with the radioactive tracer 18F-NOS may be a useful tool&#xD;
      for detecting the early stages of these diseases. The safety of 18F-NOS during the study will&#xD;
      also be assessed. All PET imaging will be performed with a CTI/Siemens Biograph 40 PET/CT&#xD;
      scanner. Protocol was revised to add new imaging modality, Biograph mMR PET-MR scanner in&#xD;
      order to investigate new hardware and software in order to optimize scanning procedures in&#xD;
      order to refine image quality so that we can apply the findings to future standard clinical&#xD;
      scans and research imaging studies. Ten additional status-post OHT patients who are scheduled&#xD;
      for standard of care endomyocardial biopsy for allograft rejection surveillance will undergo&#xD;
      PET/MR imaging with [18F](+/-)NOS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nitric oxide (NO) is an important and unique mediator of a variety of physiological and&#xD;
      pathological processes. NO is generated from the oxidation of L-arginine to L-citrulline in a&#xD;
      two-step process by nitric oxide synthase (NOS) enzymes. In the NOS family, there are two&#xD;
      constitutive isozymes of NOS, neuronal NOS (nNOS) and endothelial NOS (eNOS), and one&#xD;
      inducible isozyme (iNOS). The three isozymes of NOS are expressed in different tissues to&#xD;
      generate NO for specific physiological roles. nNOS generates NO as a neurotransmitter and&#xD;
      neuromodulator, mainly in brain and peripheral nerve cells; eNOS regulates blood pressure,&#xD;
      and blood flow primarily in vascular endothelial cells. The induction of iNOS occurs by&#xD;
      various inflammatory stimuli (e.g., endotoxin) in activated macrophages and other types of&#xD;
      cells and plays a crucial role in the host defense and the inflammatory processes.&#xD;
&#xD;
      Normally, the basal level of NO in all parts of the body is very low, mainly due to the&#xD;
      constitutive nNOS and eNOS. In contrast, once expressed, iNOS can continue to generate NO in&#xD;
      large amounts (up to Î¼M concentrations) for a prolonged period of time. Studies have shown&#xD;
      that production of NO by iNOS is implicated in a variety of acute and chronic inflammatory&#xD;
      diseases (e.g., sepsis, septic shock, organ transplant rejection, vascular dysfunction in&#xD;
      diabetes, asthma, arthritis, multiple sclerosis, and inflammatory diseases of the gut). iNOS&#xD;
      activity has also been found in many tumors. Because of the central role of iNOS in&#xD;
      NO-related diseases, numerous efforts have been made to develop iNOS inhibitors as&#xD;
      pharmaceuticals ranging from the nonselective L-arginine analogues to the selective&#xD;
      inhibitors reported recently. Some inhibitors of iNOS have shown promising results in animal&#xD;
      models of sepsis, lung inflammation, arthritis, and autoimmune diabetes. Therefore, the&#xD;
      development of a radiolabeled iNOS inhibitor for probing iNOS expression in vivo using&#xD;
      noninvasive positron emission tomography (PET) imaging will be of tremendous value to the&#xD;
      study and treatment of NO-related diseases.&#xD;
&#xD;
      Acute allograft rejection is the major contributor to mortality in patients receiving&#xD;
      orthotopic heart transplantation (OHT). Specifically, iNOS has been thought to be the main&#xD;
      NOS involved in producing NO that is active in acute cardiac allograft rejection.&#xD;
      Up-regulation of iNOS occurs in macrophage cellular infiltrates and later within the graft&#xD;
      parenchymal cells. In human cardiac transplantation a positive correlation has shown between&#xD;
      iNOS expression and left ventricular contractile dysfunction measured by echocardiography and&#xD;
      Doppler techniques. We have recently developed a novel PET radiotracer, [18F](+/-)NOS,&#xD;
      designed to measure cellular iNOS activity. This study evaluates the feasibility of the&#xD;
      method in OHT patients undergoing surveillance endomyocardial biopsy as part of their normal&#xD;
      post-transplant evaluation for potential allograft rejection. More specifically, it will&#xD;
      compare the myocardial kinetics of this radiotracer measured by PET with tissue measurements&#xD;
      of iNOS measured by immunohistochemistry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Measure Free Fatty Acid by Imaging Patients With Increased Levels of iNOS Using [18F](+/-)NOS.</measure>
    <time_frame>24-72 hours post [18F](+/-)NOS injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine Human Dosimetry in Both Normal Adult Healthy Volunteers and Heart Transplant Patients.</measure>
    <time_frame>24-72 hours post [18F](+/-)NOS injection</time_frame>
    <description>All subjects will receive a single intravenous administration of 7 mCi of [18F](+/-)NOS followed by dynamic PET/CT imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Patients With Post Orthotopic Heart Transplantation Status</condition>
  <arm_group>
    <arm_group_label>Dosimetry Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (3 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kinetic Analysis Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F](+/-)NOS</intervention_name>
    <description>Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis</description>
    <arm_group_label>Dosimetry Group</arm_group_label>
    <arm_group_label>Kinetic Analysis Group</arm_group_label>
    <other_name>6-(1/2)(2-18F-fluoropropyl)-4-methylpyridin-2-amine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The OHT patients will be undergoing surveillance endomyocardial biopsy and will&#xD;
             Patients 21 years of age or older of either sex, who are status-post OHT and normal&#xD;
             healthy volunteers (2 women and 2 men) will be enrolled.be on standard&#xD;
             immunosuppressive therapy and anti-hyperlipidemic, anti-hypertensive and anti-diabetic&#xD;
             therapies as needed. &quot;Healthy volunteer&quot; is someone who has volunteered to be imaged&#xD;
             and who, based on physical exam and baseline electrocardiogram, has no evidence of&#xD;
             cardiovascular disease, is not on medication, such as steroids, that will interfere&#xD;
             with the accuracy of measuring [18F](+/-)NOS activity and is not under the care of a&#xD;
             physician for any active medical conditions.&#xD;
&#xD;
          2. Able to give informed consent.&#xD;
&#xD;
          3. Not currently pregnant or nursing: Female subjects must be either: surgically sterile&#xD;
             (has had a documented bilateral oophorectomy and/or documented hysterectomy), post&#xD;
             menopausal (cessation of menses for more than 1 year), or of childbearing potential&#xD;
             for whom a urine pregnancy test (with the test performed within the 24 hour period&#xD;
             immediately prior to administration of [18F](+/-)NOS) is negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with an unstable cardiovascular (e.g., severe rejection) or other clinical&#xD;
             condition (e.g., active severe infection) that in the opinion of the Principal&#xD;
             Investigator or designee or Dr. Ewald precludes participation in the study.&#xD;
&#xD;
          2. Unable to tolerate 60-90 mins of PET imaging or is claustrophobic.&#xD;
&#xD;
          3. Normal volunteers with evidence of cardiovascular disease or other diseases based on&#xD;
             clinical evaluation and/or blood laboratory tests, which are judged by the Principal&#xD;
             Investigator or designee to interfere with accurate determination of the of&#xD;
             [18F](+/-)NOS on such measures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Gropler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem. 1993 Jun 15;268(17):12231-4. Review.</citation>
    <PMID>7685338</PMID>
  </reference>
  <reference>
    <citation>Kaneki M, Shimizu N, Yamada D, Chang K. Nitrosative stress and pathogenesis of insulin resistance. Antioxid Redox Signal. 2007 Mar;9(3):319-29. Review.</citation>
    <PMID>17184170</PMID>
  </reference>
  <results_reference>
    <citation>Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001 Aug 1;357(Pt 3):593-615. Review.</citation>
    <PMID>11463332</PMID>
  </results_reference>
  <results_reference>
    <citation>Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev. 2005 Jun;57(2):217-52. Review.</citation>
    <PMID>15914468</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <results_first_submitted>February 7, 2018</results_first_submitted>
  <results_first_submitted_qc>July 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2020</results_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart transplant patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dosimetry Group</title>
          <description>To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (9 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.&#xD;
[18F](+/-)NOS: Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis</description>
        </group>
        <group group_id="P2">
          <title>Kinetic Analysis Group</title>
          <description>Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.&#xD;
[18F](+/-)NOS: Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dosimetry Group-measuring Radioisotope in Blood</title>
          <description>To determine its potential for use in humans, we measured the level of 18F-NOS radiopharmaceutical in patients after orthotopic heart transplantation (OHT) (3 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.&#xD;
The level of 18-F-NOS was measured at different time points in minutes after injection of the radioisotope: The measurement time points were 0/120 minutes, 30/150 minutes, 60/180 minutes, and 90/210 minutes. The imaging began from mid thigh, to the base of the brain.</description>
        </group>
        <group group_id="B2">
          <title>Kinetic Analysis Group-measuring Levels of Nitric Oxide</title>
          <description>Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="16"/>
                    <count group_id="B2" value="10"/>
                    <count group_id="B3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dosimetry and Kinetics</title>
          <description>Dosimetry group unit of measure which measures the level of radioisotopes in blood uses millicures, which is the unit of measurement to measure radioisotopes in blood. A millicure is a unit of radioactivity equal to one thousandth of a cure;3.70 x disintegrations per second.&#xD;
Kinetics is the unit of measurement to measure the amount of INOS in the blood. INOS is an enzyme which catalyses the production of nitroc oxide.</description>
          <population>The PI has left the institution and we no longer have access to this data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Measure Free Fatty Acid by Imaging Patients With Increased Levels of iNOS Using [18F](+/-)NOS.</title>
        <time_frame>24-72 hours post [18F](+/-)NOS injection</time_frame>
        <population>The PI has left the institution and all efforts to locate data have been exhausted. There is no access to study data and it therefore cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Dosimetry Group</title>
            <description>To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (9 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.&#xD;
[18F](+/-)NOS: Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis</description>
          </group>
          <group group_id="O2">
            <title>Kinetic Analysis Group</title>
            <description>Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.&#xD;
[18F](+/-)NOS: Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure Free Fatty Acid by Imaging Patients With Increased Levels of iNOS Using [18F](+/-)NOS.</title>
          <population>The PI has left the institution and all efforts to locate data have been exhausted. There is no access to study data and it therefore cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine Human Dosimetry in Both Normal Adult Healthy Volunteers and Heart Transplant Patients.</title>
        <description>All subjects will receive a single intravenous administration of 7 mCi of [18F](+/-)NOS followed by dynamic PET/CT imaging</description>
        <time_frame>24-72 hours post [18F](+/-)NOS injection</time_frame>
        <population>The PI has left the institution and all efforts to locate data have been exhausted. There is no access to study data and it therefore cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Dosimetry Group</title>
            <description>To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (9 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.&#xD;
[18F](+/-)NOS: Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis</description>
          </group>
          <group group_id="O2">
            <title>Kinetic Analysis Group</title>
            <description>Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.&#xD;
[18F](+/-)NOS: Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine Human Dosimetry in Both Normal Adult Healthy Volunteers and Heart Transplant Patients.</title>
          <description>All subjects will receive a single intravenous administration of 7 mCi of [18F](+/-)NOS followed by dynamic PET/CT imaging</description>
          <population>The PI has left the institution and all efforts to locate data have been exhausted. There is no access to study data and it therefore cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1-2 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dosimetry Group</title>
          <description>To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (9 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.&#xD;
[18F](+/-)NOS: Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis</description>
        </group>
        <group group_id="E2">
          <title>Kinetic Analysis Group</title>
          <description>Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.&#xD;
[18F](+/-)NOS: Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>there were no limitations or caveats</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Gropler, MD, Chief of Cardiovascular Imaging Laboratory</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-747-3877</phone>
      <email>groplerr@mir.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

